Abstract: An oral composition in the form of a toothpaste, powder, liquid dentifrice, mouthwash, denture cleanser, chewing gum or candy comprising one or more oral composition components selected from abrasives, binders, humectants, surfactants, fluoride ion sources, anticalculus agents and sweeteners and additionally comprising a dimethicone polyol as herein defined.

Abstract: The present invention relates to a pharmaceutical composition in a unit dosage form for peroral administration in a human or lower animal, having a gastrointestinal tract comprising a small intestine and a colon with a lumen therethrough having an inlet to the colon from the small intestine, comprising:a. a safe and effective amount of a therapeutically active agent incorporated into or coated on the surface of a dosage form selected from the group consisting of a spherical substrate, an elliptical substrate, a hard capsule, or a compressed tablet, with a maximum diameter of about 3 mm to about 10 mm; andb. an enteric polymer coating material;wherein the dosage form has a smooth surface free from edges or sharp curves; the elliptical substrate and the hard capsule have a ratio of the long to short diameters of no greater than about 1.

Abstract: The present invention relates to compositions and processes which incorporate water-soluble polymers, other than enzymes, containing .dbd.N--C(.dbd.O)-- (including PVP) and/or N-oxide groups into the wash, rinse, and/or drying cycle of a laundering process (e.g., via fabric softening compositions) for dye transfer inhibition in the subsequent wash cycle. Multiple wash cycles optimize the dye transfer inhibitor performance of these polymers, remove unwanted dye discoloration caused by dye transfer, and provide soil antiredeposition benefits.

Abstract: Compositions comprising a calcium channel blocker as an active agent and a biocompatible carrier for fixing the agent temporarily at the site of application, or precursor compounds forming such a biocompatible carrier "in situ".It is useful for the treatment of a body site to enhance tissue healing and regeneration, particularly in dental medicine and in surgery.

Abstract: The present invention relates to a pharmaceutical composition in a unit dosage form for peroral administration in a human or lower animal, having a gastrointestinal tract comprising a small intestine and a colon with a lumen therethrough having an inlet to the colon from the small intestine, comprising:a. a safe and effective amount of a therapeutically active agent incorporated into or coated on the surface of a dosage form selected from the group consisting of a spherical substrate, an elliptical substrate, a hard capsule, or a compressed tablet, with a maximum diameter of about 3 mm to about 10 mm; andb. an enteric polymer coating material comprising at least one inner coating layer and one outer coating layer;wherein the dosage form has a smooth surface free from edges or sharp curves; the elliptical substrate and the hard capsule have a ratio of the long to short diameters of no greater than about 1.

Abstract: The present invention relates to a pharmaceutical composition in a unit dosage form for peroral administration in a human or lower animal, having a gastrointestinal tract comprising a small intestine and a colon with a lumen therethrough having an inlet to the colon from the small intestine, comprising:a. a safe and effective amount of a therapeutically active agent incorporated into or coated on the surface of a dosage form selected from the group consisting of a spherical substrate, an elliptical substrate, a hard capsule, or a compressed tablet, with a maximum diameter of about 3 mm to about 10 mm; andb. an enteric polymer coating material;wherein the dosage form has a smooth surface free from edges or sharp curves; the elliptical substrate and the hard capsule have a ratio of the long to short diameters of no greater than about 1.

Abstract: The subject invention involves pharmaceutical compositions in dosage unit form, for peroral administration of bisacodyl to a human or lower animal having a gastrointestinal tract, with a lumen therethrough, with a small intestine and a colon with a junction therebetween, comprising:(a) a safe and effective amount of rapidly-dissolving bisacodyl means; and(b) a delivery means which prevents the release of bisacodyl from the dosage form into the lumen of the gastrointestinal tract during transport of the dosage form through the lumen until the dosage form is near the junction between the small intestine and the colon or in the colon, and which then releases the bisacodyl in the lumen near the junction between the small intestine and the colon or within the colon,The subject invention also involves methods for providing laxation for humans and lower animals in need thereof by peroral administration of such compositions.

Abstract: The present invention relates to methods of inhibiting alveolar bone resorption or the undesirable movement of teeth of a human or other animal comprising:a) administering a reservoir to the gingival tissue of the oral cavity such that the reservoir is in contact with the exposed tissue nearest to the alveolar bone to be treated wherein the reservoir is a composition having a pH which maintains an active compound in a negatively charged state and comprises a safe and effective amount of the active compound having the structure: ##STR1## wherein: n is an integer from 0 to 7 (preferably from 0 to 3, more preferably 1); R.sup.1 is hydrogen, chloro, amino, or hydroxy (preferably hydrogen or hydroxy); X is --NH--, quaternary amine, oxygen, sulfur, or a single bond (preferably --NH-- or single bond); R.sup.

Abstract: The present invention relates to a pharmaceutical composition in a unit dosage form for peroral administration in a human or lower animal, having a gastrointestinal tract comprising a small intestine and a colon with a lumen therethrough having an inlet to the colon from the small intestine, comprising:a. a safe and effective amount of rapidly dissolving bisacodyl incorporated into or coated on the surface of a dosage form selected from the group consisting of a spherical substrate, an elliptical substrate, a hard capsule, or a compressed tablet, with a maximum diameter of about 3 mm to about 10 mm; andb. an enteric polymer coating material comprising at least one inner coating layer and one outer coating layer;wherein the dosage form has a smooth surface free from edges or sharp curves; the elliptical substrate and the hard capsule have a ratio of the long to short diameters of no greater than about 1.

Abstract: The present invention relates to a pharmaceutical composition in a unit dosage form for peroral administration in a human or lower animal, having a gastrointestinal tract comprising a small intestine and a colon with a lumen therethrough having an inlet to the colon from the small intestine, comprising:a. a safe and effective amount of rapidly dissolving bisacodyl incorporated into or coated on the surface of a dosage form selected from the group consisting of a spherical substrate, an elliptical substrate, a hard capsule, or a compressed tablet, with a maximum diameter of about 3 mm to about 10 mm; andb. an enteric polymer coating material;wherein the dosage form has a smooth surface free from edges or sharp curves; the elliptical substrate and the hard capsule have a ratio of the long to short diameters of no greater than about 1.

Abstract: The present invention relates to a stable, homogenous fabric softening composition providing good static control, selected from the group consisting of:I. a liquid composition comprising: (A) from about 5% to about 40% by weight of a biodegradable quaternary ammonium fabric softening compound; (B) from about 0% to about 2.5% by weight of an electrolyte; (C)an aqueous liquid carrier; and (D) from about 0% to about 0.5% of a silicone antifoam agent; and II. a solid particulate composition comprising: (A) from about 50% to about 95% by weight of a biodegradable quaternary ammonium fabric softening compound; and (B) from about 0% to about 30% by weight of dispersibility modifier selected from the group consisting of: 1.) single-long-chain, C.sub.10 -C.sub.22 alkyl, cationic surfactant; 2.) nonionic surfactant with at least 8 ethoxy moieties; 3.) amine oxide; and 4.) mixtures thereof; wherein the quaternary ammonium fabric softening compound has the formula:(R).sub.4-m -N.sup.+ -[(CH.sub.2).sub.n -Y-R.sup.2 ].sub.

Abstract: A pharmaceutical laxative composition in unit dosage form, for peroral administration of picosulphate to a human or other animal subject, comprising a safe and effective amount of picosulphate in a rapidly dissolving matrix; and a proximal colonic delivery carrier which effects release of said picosulphate substantially near the junction between the small intestine and the colon or within the colon of said subject. This invention also involves methods for providing laxation for humans and other animals in need thereof by peroral administration of such compositions.

Abstract: The subject invention encompasses methods and compositions comprising phosphate derivatives of triclosan for treating or preventing dental plaque, gingivitis or periodontal disease, of the oral cavity in humans or lower animals.

Abstract: The present invention relates to softening compounds; stable, homogeneous, preferably concentrated, aqueous liquid and solid textile treatment compositions; and intermediate compositions and/or processes for making said compositions. The compositions of the present invention contain diester quaternary ammonium compounds wherein the fatty acyl groups have an Iodine Value of from greater than about 5 to less than about 100, a cis/trans isomer weight ratio of greater than about 30/70 when the Iodine Value is less than about 25, the level of unsaturation being less than about 65% by weight, wherein said compounds are capable of forming concentrated aqueous compositions with concentrations greater than about 13% by weight at an Iodine Value of greater than about 10 without viscosity modifiers other than normal polar organic solvents present in the raw material of the compound or added electrolyte.

Abstract: Compositions are disclosed containing fabric softener compound having two hydrophobic groups attached to the remainder of the compound through ester linkages (DEQA), said compositions being concentrated and containing viscosity/dispersibility modifiers which are single long chain cationic surfactants, highly ethoxylated nonionic surfactants and/or mixtures thereof. Premixes of the DEQA and viscosity modifiers to lower the viscosity of the molten DEQA are disclosed. Processes for making aqueous liquid compositions from solid particulate compositions containing the DEQA are also disclosed.

Abstract: The present invention relates to softening compounds; stable, homogeneous, preferably concentrated, aqueous liquid and solid textile treatment compositions; and intermediate compositions and/or processes for making said compositions. The compositions of the present invention contain diester quaternary ammonium compounds wherein the fatty acyl groups have an Iodine Value of from greater than about 5 to less than about 100, a cis/trans isomer weight ratio of greater than about 30/70 when the Iodine Value is less than about 25, the level of unsaturation being less than about 65% by weight, wherein said compounds are capable of forming concentrated aqueous compositions with concentrations greater than about 13% by weight at an Iodine Value of greater than about 10 without viscosity modifiers other than normal polar organic solvents present in the raw material of the compound or added electrolyte.

Abstract: This invention relates to a pharmaceutical laxative composition in unit dosage form, for peroral administration of sennosides to a human or other animal subject, comprising a safe and effective amount of sennosides in a rapidly dissolving matrix; and a proximal colonic delivery carrier which effects release of said sennosides substantially near the junction between the small intestine and the colon or within the colon of said subject. This invention also involves methods for providing laxation for humans and other animals in need thereof by peroral administration of such compositions.

Abstract: The present invention relates to compositions and methods for inhibiting or preventing growth of dental plaque on tissues within the human oral cavity comprising topical administration, to tissues of a human oral cavity, of a composition comprising a safe and effective amount of Actinomyces viscosus fimbriae.

Abstract: The present invention relates to a tripepride having the amino acid sequence Alanine-lsoleucine-Phenylalanine. This invention also relates to methods and compositions for inhibiting growth of dental plaque on tissues within an oral cavity of a human or other animal comprising topical administration, to tissues of such oral cavity, of a composition comprising a safe and effective amount of the tripepride.

Abstract: Concentrated fabric softening compositions are described which retain viscosity upon dilution in water. The compositions comprise cationic fabric softening actives, as well as a specific combination of emulsifiers and polymers. The present invention also encompasses a method for the softening of fabrics.